Roth MKM Reiterates Buy on Zevra Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has reiterated a 'Buy' rating on Zevra Therapeutics (NASDAQ:ZVRA) and maintained a $25 price target.
October 06, 2023 | 4:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zevra Therapeutics has received a reiterated 'Buy' rating from Roth MKM, with a maintained price target of $25.
The reiterated 'Buy' rating and maintained price target by Roth MKM indicates a positive outlook for Zevra Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100